BAFF

Home
Ligands
BAFF (Human)

GtoPdb Ligand ID: 5069

Synonyms: B cell-activating factor | CD257 antigen | dendritic cell-derived TNF-like molecule

Compound class: Endogenous peptide in human, mouse or rat

Comment: The TNFSF13B precursor is also cleaved into a soluble form of the ligand.

Species: Human

References
1. Allan B, Benschop RJ, Lu J. (2013) Anti-baff-anti-il-17 bispecific antibodies. Patent number: WO2013158577A1. Assignee: Eli Lilly. Priority date: 20/04/2012. Publication date: 24/10/2013.
2. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum, 48 (11): 3253-65. [PMID:14613291]
3. Kikly KK. (2008) Immunmoglobulin specific to tumor necrosis factor (ligand) superfamily, member 13b (tnfsf13b) protein for use in treatment and prevention of autoimmune, inflammatory, respiratory system, skin , blood and cell proliferative disorders. Patent number: US7317089. Assignee: Eli Lilly And Company. Priority date: 16/08/2001. Publication date: 08/01/2008.
4. Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C. (2017) Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine, 84 (3): 267-274. [PMID:27663753]
5. Min H, Hsu H, Xiong F. (2002) Peptides and related molecules that bind to tall-1. Patent number: WO2002092620. Assignee: Amgen, Inc.. Priority date: 11/05/2001. Publication date: 21/11/2002.
6. Rixon MW, Gross JA. (2002) TACI-immunoglobulin fusion proteins. Patent number: WO2002094852. Assignee: Zymogenetics, Inc.. Priority date: 24/05/2001. Publication date: 10/08/2003.
7. Samy E, Wax S, Huard B, Hess H, Schneider P. (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol, 36 (1): 3-19. [PMID:28215100]
8. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol, 43 (6): 666-673. [PMID:34519594]

References

1. Allan B, Benschop RJ, Lu J. (2013)
Anti-baff-anti-il-17 bispecific antibodies.
Patent number: WO2013158577A1. Assignee: Eli Lilly. Priority date: 20/04/2012. Publication date: 24/10/2013.

2. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Arthritis Rheum, 48 (11): 3253-65. [PMID:14613291]

3. Kikly KK. (2008)
Immunmoglobulin specific to tumor necrosis factor (ligand) superfamily, member 13b (tnfsf13b) protein for use in treatment and prevention of autoimmune, inflammatory, respiratory system, skin , blood and cell proliferative disorders.
Patent number: US7317089. Assignee: Eli Lilly And Company. Priority date: 16/08/2001. Publication date: 08/01/2008.

4. Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C. (2017)
Biotherapies in systemic lupus erythematosus: New targets.
Joint Bone Spine, 84 (3): 267-274. [PMID:27663753]

5. Min H, Hsu H, Xiong F. (2002)
Peptides and related molecules that bind to tall-1.
Patent number: WO2002092620. Assignee: Amgen, Inc.. Priority date: 11/05/2001. Publication date: 21/11/2002.

6. Rixon MW, Gross JA. (2002)
TACI-immunoglobulin fusion proteins.
Patent number: WO2002094852. Assignee: Zymogenetics, Inc.. Priority date: 24/05/2001. Publication date: 10/08/2003.

7. Samy E, Wax S, Huard B, Hess H, Schneider P. (2017)
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Int Rev Immunol, 36 (1): 3-19. [PMID:28215100]

8. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. (2021)
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Immunopharmacol Immunotoxicol, 43 (6): 666-673. [PMID:34519594]